Clinical Trial

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 10, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of lisaftoclax.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2019-12-30; most recent amendment 2025-04-08.
Status change: Not Yet Recruiting → Recruiting 2020-03-27
Trial Details
NCT Number NCT04215809
Lead Sponsor Ascentage Pharma Group Inc.
Conditions CLL/SLL
Enrollment 144 participants
Start Date 2020-03-02
Primary Completion 2025-10-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-10